Home » Newsletter » December 2022

December 2022

In This Issue

  • CMLTO Professional Development Activities
  • Are we over activating Massive Hemorrhage Protocols in Pediatric Patients?
  • Announcements
    • Tech Assessment
  • Featured Resources
    • Bloody Easy 5: RBC Pre-Transfusion Checklist
    • Patient Pamphlet: New Version
  • Upcoming Event
    • UofT TM Round
  • Happy Holidays!

CMLTO Professional Development Activities

Effie Lau, BSc, MLT
Professional Coordinator – Quality Assurance, College of Medical Laboratory Technologists of Ontario (CMLTO)

On January 1, 2021, the CMLTO launched its updated Quality Assurance Program (QAP) which includes the Stage 1 and Stage 2 Professional Portfolio. Practising registrants are required to maintain an up-to-date Professional Portfolio each year. All Practising registrants submit their Stage 1 Portfolio by March 31st of each year, and those randomly selected for audit must submit their Stage 2 Portfolio, including their Professional Development (PD) activities, for review by QAP staff by December 31st.

What can I claim for my PD hours?

As Medical Laboratory Technologists (MLTs), we all understand the importance of maintaining and enhancing our professional practice. Therefore, the CMLTO believes that PD occurs from any activity that advances an MLT’s knowledge, skill, or judgment to provide better, higher quality services within their practice setting. After you have completed an activity, you should ask yourself, “what did I learn and how can/could I apply these learnings in my MLT practice?” If you can clearly answer this question, the activity may be claimed in your Professional Portfolio.

How do I record my PD activities?
The PD section is found in the Stage 2 Professional Portfolio. There are three requirements:

In the Key Learnings section of each activity, you will record the answer to the question above, “what did I learn and how can I apply these learnings in my MLT practice?” For example, if you reviewed a transfusion guideline and it advanced your MLT knowledge, you may claim that activity. If the activity is linked to a goal, you record how it enabled you to advance your goal in the Impact on Practice section.

To assist MLTs, the CMLTO developed a Self-Directed PD Guideline on the maximum amount of hours that MLTs can claim for certain activities (here). If you have any questions about your Professional Portfolio, please contact the QAP department at 1-800-323-9627, extension 2, or by email at qualityassurance@cmlto.com.

Are we over activating Massive Hemorrhage Protocols in Pediatric Patients?

Dylan Grimm1, Laurence Delorme1, Eric Fagan1, Na Li 2, Mark McVey3,4, Suzanne Beno5,6, Elaine Leung7,8, Lani Lieberman9,10, Troy Thompson11, Katerina Pavenski12, Jeannie Callum13, Kimmo Murto14,15

1Queen’s University, Faculty of Medicine, Kingston, ON; 2Centre for Health Informatics, University of Calgary, Calgary, AB; 3Hospital for Sick Children, Toronto, ON; 4Assistant Professor, University of Toronto, Department of Anesthesiology & Pain Medicine, Toronto, ON; 5Associate Professor, University of Toronto, Department of Pediatrics, Division of Emergency Medicine, Toronto, ON; 6Hospital for Sick Children, Toronto, ON; 7Assistant Professor, University of Ottawa Department of Pathology and Laboratory Medicine, Division of Hematology and Transfusion Medicine, Ottawa, ON; 8Children’s Hospital of Eastern Ontario (CHEO), Ottawa, ON; 9Assistant Professor, University of Toronto, Department of Laboratory Medicine & Pathology, Toronto, ON; 10University Health Network: Toronto General Hospital, Toronto, ON; 11Ontario Regional Blood Coordinating Network, Toronto, ON; 12Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; 13Professor, Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON; 14Associate Professor, University of Ottawa, Department of Anesthesiology & Pain Medicine, Ottawa, ON; 15CHEO Research Institute, Ottawa, ON.

Hemorrhage is the leading cause of preventable death within the first 24 hours after trauma in children and adults. In May 2021, the Ontario Regional Blood Coordinating Network (ORBCoN) disseminated the first provincial pediatric and adult evidence-based massive-hemorrhage-protocol (MHP) and associated toolkit content including recommendations for 8 quality improvement (QI) metrics.1,2 The initial QI data have provided insight on MHP trends in Ontario hospitals, and highlighted differences between adult and pediatric MHP activations.
MHP activation data and 28 day follow-up from 8 Ontario hospitals including 2 pediatric tertiary care centers was retrospectively collected (January 2019-May 2022). Patient demographics, mortality rates and 8 MHP QI metrics were entered in REDCap© data-collection-tool, and differences between adult versus pediatric MHP quality metrics were assessed.

In total, 363 MHP activations were reported and available for comparison (44 pediatric, 319 adult) (Table 1). Hemorrhage from traumatic injury accounted for most activations in children (59%) and adults (40%). Analysis of the QI metrics (Table 2) showed children were more likely to experience MHP over-activation (66 vs. 39%, p=0.002; correct activation defined as blood component requirements of adults>6 RBC units; children> 40 ml/kg, or death due to bleeding within first 24-hours) and less likely to experience a delay in RBC transfusion (4.5 vs 13%, p=0.003 (defined as > 15 minutes from protocol activation). Both cohorts reported ≥ 20% of patients had delayed tranexamic acid (TXA) administration and both cohorts had 11% of patients with uncorrected hypothermia at MHP termination. RBC over-transfusion (Hgb>110 g/L at MHP termination) was common and reported in 45% and 31% of children and adults, respectively, and 9.1% and 16% in children and adults reported blood component wastage.

MHP over-activation was more common in children compared with adults, with pediatric patients tending to see more unecessary activations as well as over-transfusions. One possible explanation is that hemorrhagic shock in pediatric patients may have a delayed onset or be more challenging to diagnose. However, these concerns should be balanced against transfusion risks, including hyperkalemia, hypoglycemia, and circulatory overload. In both cohorts, timely administration of TXA and management of hypothermia should be improved, as both have been shown to improve mortality in hemorrhage.

One limitation of this analysis is low numbers of pediatric MHP activations. However, at the time of this newsletter publication, there will be approximately 1700 MHP activations collected in the RedCAP® system, around 100 of which are expected to be pediatric activations. The data analysis is ongoing. The MHP QI metrics system is a valuable tool to identify the areas of improvement, with an overall goal of improving outcomes in patients receiving MHP.

Table 1. Demographics of pediatric and adult massive hemorrhage protocal activation cohorts

VariableOverall N=363Pediatric, N = 44Adult, N = 319
MHP Activation Age, n (%)   
Neonate (< =1 month)3 (0.8)3 (6.8)0 (0)
Pediatric (>1 month to 12 yrs)22 (6.1)22 (50)0 (0)
Adolescent (13-17 yrs)19 (5.2)19 (43)0 (0)
Adult (>17 yrs)319 (88)0 (0)319 (100)
MHP activations by hospital, n (%)   
B10 (2.8)0 (0)10 (3.1)
C33 (9.1)33 (75)0 (0)
D61 (17)2 (4.5)59 (18)
E87 (24)1 (2.3)86 (27)
F37 (10)1 (2.3)36 (11)
G3 (0.8)0 (0)3 (0.9)
H5 (1.4)5 (11)0 (0)
I127 (35)2 (4.5)125 (39)
MHP Activation Location, n (%)   
ER209 (58)29 (66)180 (56)
OR46 (13)4 (9.1)42 (13)
Ward14 (3.9)0 (0)14 (4.4)
ICU80 (22)9 (20)71 (22)
Obstetrics10 (2.8)0 (0)10 (3.1)
Other4 (1.1)2 (4.5)2 (0.6)
MHP Type, n (%)   
Trauma155 (43)26 (59)129 (40)
Gastrointestinal bleed88 (24)2 (4.5)86 (27)
Surgical bleed non-cardiac surgery29 (8.0)4 (9.1)25 (7.8)
Cardiac surgery13 (3.6)1 (2.3)12 (3.8)
Obstetrics18 (5.0)0 (0)18 (5.6)
Vascular25 (6.9)4 (9.1)21 (6.6)
Other32 (8.8)7 (16)25 (7.8)
Unknown3 (0.8)0 (0)3 (0.9)
Status at hospital Discharge up to 28 days, n (%)   
Home154 (43)19 (43)135 (43)
Rehab29 (8.2)5 (11)24 (7.7)
Chronic Care21 (5.9)1 (2.3)20 (6.4)
Deceased151 (43)19 (43)132 (42)
N/A – Patient expired before 60 mins26 (7.2)0 (0)26 (8.2)
N/A – No transfer/definitive care provided254 (70)43 (98)211 (66)
Note: MHP=massive hemorrhage protocol; ER=emergency room; OR=operating room; ICU=intensive care unit; N/A=not applicable

Table 2: Comparison of pediatric with adult massive hemorrhage protocol quality indicators, years 2019-2022

Primary Outcomes, n (%)Pediatric  (N=44)Adult  (N=319)p-value*
System-related:   Proportion of MHP over-activation [adults>6 RBC units; children> 40 ml/kg or death due to bleeding within first 24-hours]  29 (66)124 (39)0.002
Process-related:   Proportion of patients not administered RBCs within 15 mins of MHP activation  2 (4.5)41 (13)0.003
  Proportion of patients not receiving TXA within 1 hour of MHP Activation  12 (27)64 (20)0.32218??
Patient-related:   Proportion not achieving temperature ≥ 35°C at MHP termination  5 (11)35 (11)>0.99
  Secondary Outcomes, n (%)     
System-related:   Proportion where initiation for patient transfer did not occur within 60 minutes of MHP activation0 (0)27 (8.5)<0.001
Process-related:   Proportion not transitioned to group-specific RBCs and plasma within 90 mins of arrival/onset of hemorrhage  2 (4.5)21 (6.6)0.085
  Proportion of patients with blood component/product wastage  4 (9.1)52(16)0.39
Patient-related:   Proportion with Hgb levels < 60 g/L  0 (0)16 (5.0)0.35
  Proportion Hgb levels > 110 g/L  20 (45)100 (31)0.14
*Fisher’s Exact Test; Pearson Chi-Squared Test
Note: MHP=massive hemorrhage protocol; RBC=red blood cell; TXA=tranexamic acid; Hgb=hemoglobin


  1. Callum JL, Yeh CH, Petrosoniak A, et al. A regional massive hemorrhage protocol developed through a modified Delphi technique. CMAJ. 2019;7(3):E546-E561.
  2. Cope S, Callum J, Pavenski K, et al. Ontario’s Massive Hemorrhage Toolkit. Transfus Med Rev. 2022;36(1):67.
  3. Holcomb JB, Moore EE, Sperry JL, et al. Evidence-Based and Clinically Relevant Outcomes for Hemorrhage Control Trauma Trials. Ann Surg. 2021;273(3):395-401.
  4. Leonard JC, Josephson CD, Luther JF, et al. Life-Threatening Bleeding in Children: A Prospective Observational Study. Crit Care Med. 2021;49(11):1943-1954.


Tech Assessment

The Bloody Easy Technologist Assessment program is available on the new ORBCoN Learning Management System (LMS) and Surge Learning platforms.

A communication will be coming with instructions to provide site administrator information for access to the ORBCoN LMS and guidance for current Surge Learning clients.

If you have any questions please reach out to alison.wendt@sunnybrook.ca

Featured Resources

Bloody Easy 5: RBC Pre-Transfusion Checklist

Patient Pamphlet: New Version

Upcoming Events

UofT TM Rounds

December 15, 2022 @12pm-1pm

Running Big Data by Dr. Ruchika Goel

Virtual Session Only

Happy Holidays!